Despite significant advances in diagnosis and treatment of heart diseases, cardiomyopathies remain the most prevalent cause of death in developed countries. Mutations in cardiac troponin T (cTnT) are responsible for ~7% of all familial hypertrophic cardiomyopathy (FHC) cases. Patients carrying these FHC related cTnT mutations show a high incidence of sudden death without the classical increase in the left ventricular heart wall seen in FHC patients with mutations in other proteins. This proposal focuses on the role of the proteasome in troponin related cardiomyopathies. The molecular mechanisms that regulate the cardiac proteasome and their role in cardiomyopathies are unknown. Transgenic mice expressing a mutant (I79N) cTnT that is associated with FHC exhibited changes in both post-translational modifications of proteasome subunits and the activity of the proteasome, but did not cause significant changes in the expression of the proteasome subunits investigated. Changes in phosphorylation levels of the proteasome were observed concomitant with decreases in all three 20S and 26S proteasome activities. It is critical to understand the importance of the proteasome system in cardiomyopathies to be able to properly target this key proteolytic complex for future cardiovascular benefit. The amount of a key phosphatase associated with the 20S proteasome is also decreased in 20S proteasomes isolated from I79N hearts. This is important since our results also suggest that the kinases and phosphatases associated with the proteasome complex inside the heart are important modulators of the proteasome activity, and that the cardiac proteasome is unlike proteasomes from other tissues. Based upon our results we hypothesize: 1) Significant increases in myofilament Ca2+-sensitivity (>0.1pCa units) contribute to cellular alterations in signaling that lead to proteasome dysfunction which results in increased ubiquitinated proteins and cardiac dysfunction, 2) Some FHC related mutations in troponin directly affect the ability of these proteins to be degraded by the proteasome and alter proteasome activity, and 3) Kinases and phosphatases function as associating proteins for proteasomal complexes in the Troponin-related cardiomyopathies;they play a critical role in modulating the proteasomal function as part of the proteasomal subproteome. To investigate these hypotheses we will investigate three specific aims: 1) To Delineate the Roles of the 20S and 26S Proteasomes in Troponin-related Cardiomyopathies, 2) To Characterize the Temporal Profile of the Proteasome complexes in Troponin-related Cardiomyopathies, and 3) To Characterize Cardiomyopathy Induced Phosphorylation Changes in 26S Proteasomes.

Public Health Relevance

Familial hypertrophic cardiomyopathy (FHC) is the most common inherited heart disease with a prevalence of at least 0.2% and is the most common cause of sudden death in adolescents and young adults, especially in athletes. Dysfunction of the ubiquitin proteasome system (UPS) has been associated pressure overload induced hypertrophy, ischemia/reperfusion, and congestive heart failure. Investigating the role of the proteasome in FHC will give critical insights into proteasomal function in cardiomyopathies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL096819-03
Application #
8257898
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Adhikari, Bishow B
Project Start
2010-05-01
Project End
2015-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
3
Fiscal Year
2012
Total Cost
$380,944
Indirect Cost
$133,444
Name
University of California Davis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Cui, Ziyou; Scruggs, Sarah B; Gilda, Jennifer E et al. (2014) Regulation of cardiac proteasomes by ubiquitination, SUMOylation, and beyond. J Mol Cell Cardiol 71:32-42
Cui, Ziyou; Gilda, Jennifer E; Gomes, Aldrin V (2014) Crude and purified proteasome activity assays are affected by type of microplate. Anal Biochem 446:44-52
Puglisi, Jose L; Goldspink, Paul H; Gomes, Aldrin V et al. (2014) Influence of a constitutive increase in myofilament Ca(2+)-sensitivity on Ca(2+)-fluxes and contraction of mouse heart ventricular myocytes. Arch Biochem Biophys 552-553:50-9
Jamart, C├ęcile; Gomes, Aldrin V; Dewey, Shannamar et al. (2014) Regulation of ubiquitin-proteasome and autophagy pathways after acute LPS and epoxomicin administration in mice. BMC Musculoskelet Disord 15:166
Wecksler, Aaron T; Hwang, Sung Hee; Wettersten, Hiromi I et al. (2014) Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB. Anticancer Drugs 25:433-46
Ghosh, Rajeshwary; Gilda, Jennifer E; Gomes, Aldrin V (2014) The necessity of and strategies for improving confidence in the accuracy of western blots. Expert Rev Proteomics 11:549-60
Gilda, Jennifer E; Gomes, Aldrin V (2013) How phosphorylated can it get? Cardiac myosin binding protein C phosphorylation in heart failure. J Mol Cell Cardiol 62:108-10
Gilda, Jennifer E; Gomes, Aldrin V (2013) Stain-Free total protein staining is a superior loading control to *-actin for Western blots. Anal Biochem 440:186-8
Gomes, Aldrin V; Waddell, Dave S; Siu, Rylie et al. (2012) Upregulation of proteasome activity in muscle RING finger 1-null mice following denervation. FASEB J 26:2986-99
Hwee, Darren T; Gomes, Aldrin V; Bodine, Sue C (2011) Cardiac proteasome activity in muscle ring finger-1 null mice at rest and following synthetic glucocorticoid treatment. Am J Physiol Endocrinol Metab 301:E967-77

Showing the most recent 10 out of 11 publications